BioMarin Pharmaceutical reaffirms its long-term financial guidance, projecting approximately $4 billion in total revenues by 2027, a 40% Non-GAAP Operating Margin starting in 2026, and over $1.25 billion in annual operating cash flow starting in 2027, with a mid-teen CAGR for total revenues through 2034.